Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DSCR 1 CRISPR/Cas9 KO Plasmid (h): sc-402694
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DSCR 1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DSCR 1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DSCR 1 Antibody (G-2): sc-377507
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DSCR 1 CRISPR/Cas9 KO Plasmid (h) | sc-402694 | 20 µg | $397.00 |
Overview
RCAN1 (DSCR1) encodes a calcineurin-interacting protein that acts as an endogenous regulator of Ca2+-dependent signaling by modulating calcineurin phosphatase activity. Through this interaction, DSCR1 influences NFAT-driven transcriptional programs that govern stress responses, cell growth, and differentiation, and it intersects with MAPK and oxidative stress pathways. RCAN1 expression is responsive to cellular stressors and cytokine signaling, linking it to dynamic control of transcriptional outputs in multiple tissues. Dysregulated RCAN1 activity has been associated with neurodevelopmental phenotypes and altered vascular and immune signaling, providing a mechanistic handle to study pathway imbalance in disease-relevant contexts.
DSCR 1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RCAN1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RCAN1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RCAN1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DSCR 1 protein expression.
This CRISPR knockout system enables efficient generation of RCAN1-deficient cell models for investigation of DSCR 1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RCAN1 exon(s) critical for DSCR 1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RCAN1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by DSCR 1 CRISPR/Cas9 KO Plasmid (h) and DSCR 1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RCAN1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by DSCR 1 HDR Plasmid (h) and DSCR 1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RCAN1 homology arms to support homology-directed repair at defined RCAN1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.